Hormones Plant

History

2023: Plant construction begins

In June 2023, the foundation of a pharmaceutical plant for the production of hormonal drugs was laid in St. Petersburg. The company was named Hormones Plant. The project is being implemented by Solopharm.

9.5 billion rubles will be spent on the construction of a pharmaceutical factory. The area of ​ ​ the plant will be 13,260 square meters. 250 workers will receive places in production. The capacity of five production lines is estimated at 1.19 billion units per year.

Solopharm has begun construction of a pharmaceutical plant for the production of hormonal drugs

The enterprise building was designed by German architects from d/g consults GmbH. The project is based on a matrix system. It involves the presence of modular walls and facades that allow you to quickly transform sterile rooms.

As part of the new project, Solopharm expects to develop and release forty hormonal drugs in such areas as pulmonology (bronchial asthma), skin diseases (dermatitis, psoriasis, eczema), otolaryngology (sinusitis, rhinitis, otitis) and ophthalmology (conjunctivitis, keratitis and other inflammatory eye diseases).

According to the general director of the marketing agency DSM Group Sergey Shulyak, the market for hormonal drugs in Russia is quite competitive, it is still attended by large Western companies. However, their marketing activity has ceased since the end of February 2022, and their presence in the market has become less noticeable.

A window of opportunity has appeared for Russian pharmaceutical companies. Western companies have ceased to be advertised, and Russian companies continue to actively work with doctors and promote their products. So the dominance of foreign producers is coming to naught, they are gradually being supplanted by Russian manufacturers, the expert says. As Shulyak notes, the demand for various hormonal drugs in the country is high both in the pharmacy market and in the state segment. The market consumes more and more high-quality drugs and, I think, Solopharm sees these prospects, "he told RBC.[1]

Notes